In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to include adults aged 50 to 59 who face a heightened risk from respiratory syncytial virus (RSV) due to underlying health conditions. This expanded approval marks a significant move in Canada’s battle against RSV, a respiratory virus that, […]
In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately 540 million ordinary shares in Haleon, one of the largest consumer healthcare companies in the world. This sale represents about 5.9% of Haleon’s total share capital and reflects Pfizer’s ongoing strategy to reduce its non-core assets. Pfizer, […]
The U.S. Food and Drug Administration (FDA) has officially broadened the age indication for GSK plc’s (LSE/NYSE: GSK) AREXVY, marking it as the first adjuvanted Respiratory Syncytial Virus (RSV) vaccine authorized for adults aged 50-59 who are at heightened risk of severe outcomes from the virus. This extension builds on the existing approval for individuals […]
GSK plc (LSE/NYSE: GSK), a global healthcare leader, has completed the acquisition of Elsie Biotechnologies, a private biotechnology company based in San Diego, for a deal valued at up to $50 million (approximately £39 million). This acquisition marks a significant enhancement in GSK’s research and development capabilities, particularly in the promising field of oligonucleotide therapeutics. […]
GSK plc announced the results of the ZOSTER-049 phase III long-term follow-up trial, showcasing that the Shingrix (Recombinant Zoster Vaccine or RZV) maintains high efficacy against shingles for more than a decade in adults aged 50 and above. The detailed findings will be presented at the forthcoming ESCMID Global 2024 event in Barcelona, Spain. The […]
In a significant development for the treatment of chronic hepatitis B (CHB), GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to bepirovirsen, an investigational antisense oligonucleotide (ASO). This milestone is a testament to the potential of bepirovirsen in addressing the unmet medical needs of […]
GSK plc (LSE/NYSE: GSK) has reached a pivotal milestone in the prevention of shingles (herpes zoster) in China, with the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) now reviewing the regulatory application for Shingrix (Recombinant Zoster Vaccine or RZV) for adults aged 18 years and over at increased risk. […]
GSK plc has unveiled promising results from the DREAMM-7 phase III trial, which highlights a notable advancement in the treatment of relapsed or refractory multiple myeloma. The trial compared the effectiveness of Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BorDex) against the standard of care daratumumab plus BorDex combination. The findings, set to […]
In a landmark decision, the European Commission has approved GSK plc’s Omjjara (momelotinib), introducing a revolutionary treatment for adult myelofibrosis patients suffering from moderate to severe anaemia. This authorization positions Omjjara as the first medicine in the EU specifically targeting disease-related splenomegaly (enlarged spleen) or symptoms in this patient demographic, whether newly diagnosed or previously […]
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership with GSK, to evaluate the potential of combining LIXTE’s LB-100 with GSK’s PD-1-blocking antibody, dostarlimab-gxly, in treating ovarian clear cell carcinoma (OCCC). The University of Texas MD Anderson Cancer Center is conducting this trial, with LIXTE providing […]